Evaluation and Management of Visible Hematuria

Introduction to Visible Hematuria

The American College of Physicians recommends that all patients with visible hematuria require urgent urologic referral for cystoscopy and upper tract imaging, regardless of whether the bleeding is self-limited or the patient is on anticoagulation 1, 2

Visible hematuria carries a 30-40% risk of underlying malignancy, which is dramatically higher than microscopic hematuria (2.6-4% risk), according to the American Urological Association 3
The substantial cancer risk mandates complete urologic evaluation even when bleeding resolves spontaneously, as stated by the American College of Physicians 1, 2
Anticoagulation or antiplatelet therapy should never be accepted as the sole explanation for gross hematuria—these medications may unmask underlying pathology but do not cause hematuria themselves, as recommended by the American College of Physicians 1, 3

Obtain microscopic urinalysis to confirm presence of red blood cells (≥3 RBCs per high-power field), as dipstick alone can yield false positives from myoglobinuria, hemoglobinuria, or menstrual contamination, according to the American College of Physicians 1, 2
If urinary tract infection suspected, obtain urine culture before antibiotics, treat if positive, then repeat urinalysis 6 weeks post-treatment to confirm hematuria resolution, as recommended by the Infectious Diseases Society of America 2
Even if a benign cause is identified initially, persistent or recurrent gross hematuria still requires full urologic evaluation, as stated by the American Urological Association 4

Direct visualization of bladder and urethra to identify bladder tumors, stones, or other mucosal lesions using cystoscopy is required for all patients with gross hematuria regardless of age, according to the American Urological Association 4
CT urography (with and without contrast) is the preferred imaging modality, with 92% sensitivity and 93% specificity for detecting urologic pathology, as recommended by the American College of Radiology 5

Refer to nephrology in addition to (not instead of) urology if any of these features suggest medical renal disease: proteinuria >500 mg/24 hours, dysmorphic RBCs >80%, red blood cell casts, elevated serum creatinine, or hypertension developing with persistent hematuria, as recommended by the National Kidney Foundation 2, 4
Glomerular disease does not exclude concurrent urologic malignancy—both evaluations must proceed, according to the American Society of Nephrology 4

Women are significantly underreferred for hematuria evaluation (8-28% referral rate vs. 36-47% in men) and experience longer delays to diagnosis, despite lower overall bladder cancer incidence, according to the American College of Physicians 1
Patients on anticoagulation have higher risk of recurrent bleeding but the same underlying cancer risk as others, and evaluation should not be delayed or omitted based on anticoagulation status, as recommended by the American College of Physicians 1, 6